Creative Medical TechnologyCELZ
13F holders, Q4 2024 (December 31)8holders −2
1new positions
3sold out
$2.39avg. 13F price*
At the end of Q4 2024, 8 institutions reported holding Creative Medical Technology (CELZ) in their 13F filings, down 2 from Q3 2024. 1 opened new positions and 3 sold out. The largest holders were Vanguard Group Inc. ($42K), Geode Capital Management, LLC ($25K) and Tower Research Capital LLC (TRC) ($4K).
- Company
- Creative Medical Technology
- CUSIP
- 22529Y408
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $25K |
| Exits | 3 | $146K |
All 13F filers, Q3 2024 → Q4 2024: 10,583 shares bought and 49,909 shares sold, net −39,326 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Vanguard Group Inc. | 0.00% | No change | 17,629 | $42K |
| Geode Capital Management, LLC | 0.00% | New | 10,308 | $25K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +17.5% | 1,648 | $4K |
| Osaic Holdings, Inc. | 0.00% | Add +29.7% | 131 | $302 |
| Bank of America Corp. | 0.00% | Reduce -6.9% | 122 | $281 |
| Morgan Stanley | 0.00% | No change | 20 | $46 |
| UBS Group AG | 0.00% | Reduce -100.0% | 1 | $2 |
| TD Waterhouse Canada Inc. | 0.00% | No change | 1 | $2 |
"% of holder's portfolio" is CELZ's weight in each manager's 13F, not the share of Creative Medical Technology the manager owns.